Arvinas reports exploratory ARV-102 biomarker findings in Parkinson’s disease
Company / institutional announcement · Arvinas
Source published: · Event / reporting date: 2026-10-07
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Arvinas presented final Phase 1 findings for its brain-penetrant LRRK2 degrader ARV-102 in 24 patients with Parkinson’s disease treated for 28 days. Exploratory changes in eye movement measurements correlated with reductions in cerebrospinal fluid LRRK2 and changes in pathway biomarkers. The trial was not designed to establish clinical efficacy or effects on disease progression.
Why it may matter
The biomarker associations support further neurological degrader studies, but larger, longer trials are needed to separate exploratory signals from meaningful clinical benefit.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections